HDAC1 promotes the migration of human myeloma cells via regulation of the lncRNA/Slug axis

Zheng,Lisha; Zhang,Ang; Liu,Jishan; Liu,Min; Zhang,Yikun

doi:10.3892/ijmm.2021.5058

HDAC1 promotes the migration of human myeloma cells via regulation of the lncRNA/Slug axis

Authors:
- Lisha Zheng
- Ang Zhang
- Jishan Liu
- Min Liu
- Yikun Zhang
View Affiliations

Affiliations: School of Biological Science and Medical Engineering, Beihang University, Beijing 100191, P.R. China, Department of Hematology, PLA Strategic Support Force Characteristic Medical Center, Beijing 100101, P.R. China
Published online on: November 2, 2021 https://doi.org/10.3892/ijmm.2021.5058
Article Number: 3
Copyright: © Zheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Understanding the mechanisms underlying malignancy in myeloma cells is important for targeted treatment and drug development. Histone deacetylases (HDACs) can regulate the progression of various cancer types; however, their roles in myeloma are not well known. In the present study, the expression of class I HDACs in myeloma cells and tissues was evaluated. Furthermore, the effects of HDAC1 on the migration of myeloma cells and the associated mechanisms were investigated. Among the class I HDACs evaluated, HDAC1 was upregulated in both myeloma cells and tissues. Targeted inhibition of HDAC1 suppressed the migration of myeloma cells. Of the assessed transcription factors, small interfering (si)‑HDAC1 decreased the expression of Slug. Overexpression of Slug reversed the si‑HDAC1‑mediated suppressed migration of myeloma cells. Mechanistically, the results revealed that HDAC1 regulated the mRNA stability of Slug, while it had no effect on its transcription or nuclear export. Furthermore, HDAC1 negatively regulated the expression of long non‑coding RNA (lncRNA) NONHSAT113026, which could bind with the 3'‑untranslated region of Slug mRNA to facilitate its degradation. The present study demonstrated that HDAC1 promoted the migration of human myeloma cells via regulation of lncRNA/Slug signaling.

View Figures

View References

1	Landgren O and Morgan GJ: Biologic frontiers in multiple myeloma: From biomarker identification to clinical practice. Clin Cancer Res. 20:804–813. 2014. View Article : Google Scholar
2	Reisenbuckler C: Multiple myeloma and diagnostic imaging. Radiol Technol. 85:391–413. 2014.PubMed/NCBI
3	Orlowski RZ: Why proteasome inhibitors cannot ERADicate multiple myeloma. Cancer Cell. 24:275–277. 2013. View Article : Google Scholar : PubMed/NCBI
4	McCullough KB, Hobbs MA, Abeykoon JP and Kapoor P: Common adverse effects of novel therapies for multiple myeloma (MM) and their management strategies. Curr Hematol Malig Rep. 13:114–124. 2018. View Article : Google Scholar : PubMed/NCBI
5	Naymagon L and Abdul-Hay M: Novel agents in the treatment of multiple myeloma: A review about the future. J Hematol Oncol. 9:522016. View Article : Google Scholar : PubMed/NCBI
6	Ria R, Reale A and Vacca A: Novel agents and new therapeutic approaches for treatment of multiple myeloma. World J Methodol. 4:73–90. 2014. View Article : Google Scholar : PubMed/NCBI
7	Varga C, Laubach J, Hideshima T, Chauhan D, Anderson KC and Richardson PG: Novel targeted agents in the treatment of multiple myeloma. Hematol Oncol Clin North Am. 28:903–925. 2014. View Article : Google Scholar : PubMed/NCBI
8	Kelly T, Børset M, Abe E, Gaddy-Kurten D and Sanderson RD: Matrix metalloproteinases in multiple myeloma. Leuk Lymphoma. 37:273–281. 2000. View Article : Google Scholar : PubMed/NCBI
9	Takimoto M, Ogawa K, Kato Y, Saito T, Suzuki T, Irei M, Shibuya Y, Suzuki Y, Kato M, Inoue Y, et al: Close relation between 14q32/IGH translocations and chromosome 13 abnormalities in multiple myeloma: A high incidence of 11q13/CCND1 and 16q23/MAF. Int J Hematol. 87:260–265. 2008. View Article : Google Scholar : PubMed/NCBI
10	Largo C, Saéz B, Alvarez S, Suela J, Ferreira B, Blesa D, Prosper F, Calasanz MJ and Cigudosa JC: Multiple myeloma primary cells show a highly rearranged unbalanced genome with amplifications and homozygous deletions irrespective of the presence of immunoglobulin-related chromosome translocations. Haematologica. 92:795–802. 2007. View Article : Google Scholar : PubMed/NCBI
11	Bergsagel PL and Kuehl WM: Chromosome translocations in multiple myeloma. Oncogene. 20:5611–5622. 2001. View Article : Google Scholar : PubMed/NCBI
12	Issa ME, Takhsha FS, Chirumamilla CS, Perez-Novo C, Vanden Berghe W and Cuendet M: Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma. Clin Epigenetics. 9:172017. View Article : Google Scholar : PubMed/NCBI
13	Liang X, Deng M, Zhang C, Ping F, Wang H, Wang Y, Fan Z, Ren X, Tao X, Wu T, et al: Combined class I histone deacetylase and mTORC1/C2 inhibition suppresses the initiation and recurrence of oral squamous cell carcinomas by repressing SOX2. Cancer Lett. 454:108–119. 2019. View Article : Google Scholar : PubMed/NCBI
14	Jeon YJ, Ko SM, Cho JH, Chae JI and Shim JH: The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma. Int J Mol Med. 32:860–866. 2013. View Article : Google Scholar : PubMed/NCBI
15	Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP and Göttlicher M: Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 5:455–463. 2004. View Article : Google Scholar : PubMed/NCBI
16	Barneda-Zahonero B and Parra M: Histone deacetylases and cancer. Mol Oncol. 6:579–589. 2012. View Article : Google Scholar : PubMed/NCBI
17	Garcia-Guerrero E, Götz R, Doose S, Sauer M, Rodríguez-Gil A, Nerreter T, Kortüm KM, Pérez-Simón JA, Einsele H, Hudecek M and Danhof S: Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. Leukemia. 35:201–214. 2021. View Article : Google Scholar :
18	Zhou Y, Liu X, Xue J, Liu L, Liang T, Li W, Yang X, Hou X and Fang H: Discovery of peptide boronate derivatives as histone deacetylase and proteasome dual inhibitors for overcoming bortezomib resistance of multiple myeloma. J Med Chem. 63:4701–4715. 2020. View Article : Google Scholar : PubMed/NCBI
19	Sun X, Xie Y, Sun X, Yao Y, Li H, Li Z, Yao R and Xu K: The selective HDAC6 inhibitor nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma. Biosci Rep. 39:BSR201819162019. View Article : Google Scholar : PubMed/NCBI
20	Mithraprabhu S, Kalff A, Chow A, Khong T and Spencer A: Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics. 9:1511–1520. 2014. View Article : Google Scholar : PubMed/NCBI
21	Alanazi F, Kwa FAA, Burchall G and Jackson DE: New generation drugs for treatment of multiple myeloma. Drug Discov Today. 25:367–379. 2020. View Article : Google Scholar
22	Hadley M, Noonepalle S, Banik D and Villagra A: Functional analysis of HDACs in tumorigenesis. Methods Mol Biol. 1983:279–307. 2019. View Article : Google Scholar : PubMed/NCBI
23	Chen Y, Zhao H, Li H, Feng X, Tang H, Qiu C, Zhang J and Fu B: LINC01234/MicroRNA-31-5p/MAGEA3 axis mediates the proliferation and chemoresistance of hepatocellular carcinoma cells. Mol Ther Nucleic Acids. 19:168–178. 2020. View Article : Google Scholar
24	Furuyama T, Nakazawa T, Nakano I and Mori N: Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. Biochem J. 349:629–634. 2000. View Article : Google Scholar : PubMed/NCBI
25	Zhao Y, Liu Y, Lin L, Huang Q, He W, Zhang S, Dong S, Wen Z, Rao J, Liao W and Shi M: The lncRNA MACC1-AS1 promotes gastric cancer cell metabolic plasticity via AMPK/Lin28 mediated mRNA stability of MACC1. Mol Cancer. 17:692018. View Article : Google Scholar : PubMed/NCBI
26	Brabletz T, Kalluri R, Nieto MA and Weinberg RA: EMT in cancer. Nat Rev Cancer. 18:128–134. 2018. View Article : Google Scholar : PubMed/NCBI
27	Chaffer CL, San Juan BP, Lim E and Weinberg RA: EMT, cell plasticity and metastasis. Cancer Metastasis Rev. 35:645–654. 2016. View Article : Google Scholar : PubMed/NCBI
28	Quinn JJ and Chang HY: Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 17:47–62. 2016. View Article : Google Scholar
29	Yao RW, Wang Y and Chen LL: Cellular functions of long noncoding RNAs. Nat Cell Biol. 21:542–551. 2019. View Article : Google Scholar : PubMed/NCBI
30	Pu Y, Dong Z, Xia Y, Zhang M, Song J, Han J and Liu H: LncRNA NONHSAT113026 represses renal cell carcinoma tumorigenesis through interacting with NF-κB/p50 and SLUG. Biomed Pharmacother. 118:1093822019. View Article : Google Scholar
31	Al Emran A, Marzese DM, Menon DR, Stark MS, Torrano J, Hammerlindl H, Zhang G, Brafford P, Salomon MP, Nelson N, et al: Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget. 9:8206–8222. 2017. View Article : Google Scholar
32	Yeon M, Kim Y, Jung HS and Jeoung D: Histone deacetylase inhibitors to overcome resistance to targeted and immuno therapy in metastatic melanoma. Front Cell Dev Biol. 8:4862020. View Article : Google Scholar : PubMed/NCBI
33	Krumm A, Barckhausen C, Kücük P, Tomaszowski KH, Loquai C, Fahrer J, Krämer OH, Kaina B and Roos WP: Enhanced histone deacetylase activity in malignant melanoma provokes RAD51 and FANCD2-triggered drug resistance. Cancer Res. 76:3067–3077. 2016. View Article : Google Scholar : PubMed/NCBI
34	Gameiro SR, Malamas AS, Tsang KY, Ferrone S and Hodge JW: Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Oncotarget. 7:7390–7402. 2016. View Article : Google Scholar : PubMed/NCBI
35	Tang Z, Ding S, Huang H, Luo P, Qing B, Zhang S and Tang R: HDAC1 triggers the proliferation and migration of breast cancer cells via upregulation of interleukin-8. Biol Chem. 398:1347–1356. 2017. View Article : Google Scholar : PubMed/NCBI
36	Hegedüs L, Padányi R, Molnár J, Pászty K, Varga K, Kenessey I, Sárközy E, Wolf M, Grusch M, Hegyi Z, et al: Histone deacetylase inhibitor treatment increases the expression of the plasma membrane Ca²⁺ pump PMCA4b and inhibits the migration of melanoma cells independent of ERK. Front Oncol. 7:952017. View Article : Google Scholar
37	Wang Y, Shi J, Chai K, Ying X and Zhou BP: The role of snail in EMT and tumorigenesis. Curr Cancer Drug Targets. 13:963–972. 2013. View Article : Google Scholar : PubMed/NCBI
38	Ye X, Brabletz T, Kang Y, Longmore GD, Nieto MA, Stanger BZ, Yang J and Weinberg RA: Upholding a role for EMT in breast cancer metastasis. Nature. 547:E1–E3. 2017. View Article : Google Scholar : PubMed/NCBI
39	Wang Z and Liu C: MiR-153 regulates metastases of gastric cancer through Snail. Tumor Biol. 37:15509–15515. 2016. View Article : Google Scholar
40	Shirley SH, Greene VR, Duncan LM, Torres Cabala CA, Grimm EA and Kusewitt DF: Slug expression during melanoma progression. Am J Pathol. 180:2479–2489. 2012. View Article : Google Scholar : PubMed/NCBI
41	Arienti C, Tesei A, Carloni S, Ulivi P, Romeo A, Ghigi G, Menghi E, Sarnelli A, Parisi E, Silvestrini R and Zoli W: SLUG silencing increases radiosensitivity of melanoma cells in vitro. Cell Oncol (Dordr). 36:131–139. 2013. View Article : Google Scholar
42	Liu H, Chen P, Jiang C, Han J, Zhao B, Ma Y and Mardan M: Screening for the key lncRNA targets associated with metastasis of renal clear cell carcinoma. Medicine (Baltimore). 95:e25072016. View Article : Google Scholar
43	Lin CW, Wang LK, Wang SP, Chang YL, Wu YY, Chen HY, Hsiao TH, Lai WY, Lu HH, Chang YH, et al: Daxx inhibits hypoxia-induced lung cancer cell metastasis by suppressing the HIF-1α/HDAC1/Slug axis. Nat Commun. 7:138672016. View Article : Google Scholar